Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’

Will direct-to-patient telehealth prescription platforms from drugmakers like Pfizer and Eli Lilly be a tool to make healthcare more convenient for patients or an illegal strategy to increase drug sales? A group of U.S. senators has sent letters to both companies looking for an answer.